$5.08
5.83% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US68062P1066
Symbol
OLMA
Sector
Industry

Olema Pharmaceuticals Inc Stock price

$5.08
+0.33 6.95% 1M
-3.20 38.65% 6M
-0.75 12.86% YTD
-4.44 46.64% 1Y
+2.82 124.78% 3Y
-13.92 73.26% 5Y
-13.92 73.26% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.28 5.83%
ISIN
US68062P1066
Symbol
OLMA
Sector
Industry

Key metrics

Market capitalization $347.58m
Enterprise Value $-43.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.35
P/B ratio (TTM) P/B ratio 0.91
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.79m
Free Cash Flow (TTM) Free Cash Flow $-124.84m
Cash position $392.71m
EPS (TTM) EPS $-1.95
P/E forward negative
Short interest 8.75%
Show more

Is Olema Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Olema Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Olema Pharmaceuticals Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Olema Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Olema Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.43 0.43
38% 38%
-
-0.43 -0.43
38% 38%
-
- Selling and Administrative Expenses 17 17
10% 10%
-
- Research and Development Expense 125 125
34% 34%
-
-142 -142
31% 31%
-
- Depreciation and Amortization 0.43 0.43
38% 38%
-
EBIT (Operating Income) EBIT -143 -143
30% 30%
-
Net Profit -129 -129
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Olema Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Olema Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
7 days ago
Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from ongoing Phase 1b/2 study Pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer continues to advance with top-line data anticipated in 2026; trial-in-progress po...
Neutral
GlobeNewsWire
11 days ago
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
18 days ago
SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 104,400 shares ...
More Olema Pharmaceuticals Inc News

Company Profile

Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Head office United States
CEO Sean Bohen
Employees 96
Founded 2006
Website www.olema.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today